Michael Melino

3.8k total citations · 1 hit paper
55 papers, 3.0k citations indexed

About

Michael Melino is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Michael Melino has authored 55 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Cardiology and Cardiovascular Medicine, 18 papers in Surgery and 10 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Michael Melino's work include Blood Pressure and Hypertension Studies (20 papers), Lipoproteins and Cardiovascular Health (14 papers) and Atrial Fibrillation Management and Outcomes (9 papers). Michael Melino is often cited by papers focused on Blood Pressure and Hypertension Studies (20 papers), Lipoproteins and Cardiovascular Health (14 papers) and Atrial Fibrillation Management and Outcomes (9 papers). Michael Melino collaborates with scholars based in United States, Germany and United Kingdom. Michael Melino's co-authors include Francis J. Dumont, N H Sigal, Sam L. Koprak, Mary Jo Staruch, Reinilde Heyrman, James Lee, Steven G. Chrysant, Stuart Weiss, Suzanne Oparil and Víctor Fernández and has published in prestigious journals such as The Lancet, Circulation and The Journal of Experimental Medicine.

In The Last Decade

Michael Melino

54 papers receiving 2.8k citations

Hit Papers

Distinct mechanisms of suppression of murine T cell activ... 1990 2026 2002 2014 1990 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin.
    1990 510 citations Michael Melino et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael Melino United States 23 1.1k 1.0k 902 756 429 55 3.0k
Deepak Voora United States 27 774 0.7× 802 0.8× 719 0.8× 609 0.8× 181 0.4× 102 3.6k
Junji Koizumi Japan 27 2.5k 2.1× 684 0.7× 903 1.0× 1.4k 1.8× 231 0.5× 83 3.7k
A.F.H. Stalenhoef Netherlands 21 1.2k 1.1× 590 0.6× 350 0.4× 777 1.0× 254 0.6× 44 2.2k
Pedro Mata Spain 36 2.7k 2.3× 830 0.8× 580 0.6× 1.0k 1.3× 409 1.0× 119 4.0k
James H. Revkin United States 18 3.2k 2.8× 1.2k 1.2× 572 0.6× 2.3k 3.1× 420 1.0× 39 4.8k
Marina Cuchel United States 26 3.3k 2.9× 1.2k 1.2× 969 1.1× 2.3k 3.0× 394 0.9× 81 5.0k
Núria Plana Spain 29 1.4k 1.2× 689 0.7× 726 0.8× 859 1.1× 189 0.4× 161 2.9k
Claude Gagné Canada 34 2.6k 2.3× 1.1k 1.1× 463 0.5× 1.9k 2.5× 173 0.4× 77 4.0k
M. John Chapman France 28 1.4k 1.2× 571 0.6× 713 0.8× 1.1k 1.5× 422 1.0× 49 3.4k
Rex A. Parker United States 25 1.0k 0.9× 320 0.3× 1.8k 2.0× 353 0.5× 375 0.9× 45 4.0k

Countries citing papers authored by Michael Melino

Since Specialization
Citations

This map shows the geographic impact of Michael Melino's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Melino with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Melino more than expected).

Fields of papers citing papers by Michael Melino

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Melino. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Melino. The network helps show where Michael Melino may publish in the future.

Co-authorship network of co-authors of Michael Melino

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Melino. A scholar is included among the top collaborators of Michael Melino based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Melino. Michael Melino is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lip, Gregory Y.H., José Luís Merino, Maciej Banach, et al.. (2018). Impact of Body Mass Index on Outcomes in the Edoxaban Versus Warfarin Therapy Groups in Patients Underwent Cardioversion of Atrial Fibrillation (from ENSURE-AF). The American Journal of Cardiology. 123(4). 592–597. 10 indexed citations
2.
3.
Goette, Andreas, José Luís Merino, Michael D. Ezekowitz, et al.. (2016). Edoxaban versus enoxaparin–warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. The Lancet. 388(10055). 1995–2003. 177 indexed citations
4.
Fagan, Kevin J., Michael Melino, Elizabeth E. Powell, & Katharine M. Irvine. (2014). Microbial burden is associated with clinical outcomes and reduced ascites innate immune cells in non-infected ascites. Journal of Gastroenterology and Hepatology. 29. 81–81. 1 indexed citations
5.
6.
Kereiakes, Dean J., Steven G. Chrysant, Joseph L. Izzo, et al.. (2012). Long‐Term Efficacy and Safety of Triple‐Combination Therapy With Olmesartan Medoxomil and Amlodipine Besylate and Hydrochlorothiazide for Hypertension. Journal of Clinical Hypertension. 14(3). 149–157. 16 indexed citations
7.
8.
Chrysant, Steven G., Thomas Littlejohn, Joseph L. Izzo, et al.. (2012). Triple-Combination Therapy with Olmesartan, Amlodipine, and Hydrochlorothiazide in Black and Non-Black Study Participants with Hypertension. American Journal of Cardiovascular Drugs. 12(4). 233–243. 18 indexed citations
9.
Izzo, Joseph L., Steven G. Chrysant, Dean J. Kereiakes, et al.. (2011). 24-Hour Efficacy and Safety of Triple-Combination Therapy With Olmesartan, Amlodipine, and Hydrochlorothiazide: The TRINITY Ambulatory Blood Pressure Substudy. Journal of Clinical Hypertension. 13(12). 873–880. 30 indexed citations
10.
Chrysant, Steven G., James Lee, Michael Melino, Subhas S. Karki, & Reinilde Heyrman. (2010). Efficacy and tolerability of amlodipine plus olmesartan medoxomil in patients with difficult-to-treat hypertension. Journal of Human Hypertension. 24(11). 730–738. 35 indexed citations
11.
Chrysant, Steven G., et al.. (2009). Efficacy and Safety of Long‐Term Treatment With the Combination of Amlodipine Besylate and Olmesartan Medoxomil in Patients With Hypertension. Journal of Clinical Hypertension. 11(9). 475–482. 52 indexed citations
12.
Stein, Evan A., A. David Marais, Tamás Szamosi, et al.. (2009). Colesevelam Hydrochloride: Efficacy and Safety in Pediatric Subjects with Heterozygous Familial Hypercholesterolemia. The Journal of Pediatrics. 156(2). 231–236.e3. 52 indexed citations
13.
14.
Bays, Harold, Stuart Weiss, Claude Gagné, et al.. (2002). Ezetimibe added to ongoing statin therapy for treatment of primary hypercholesterolemia. Journal of the American College of Cardiology. 39. 245–245. 9 indexed citations
15.
Kastelein, John J.P., Jonathan L. Isaacsohn, Leiv Ose, et al.. (2000). Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels. The American Journal of Cardiology. 86(2). 221–223. 55 indexed citations
16.
Ose, Leiv, Michael Davidson, William Insull, et al.. (2000). Lipid‐Altering Efficacy and Safety of Simvastatin 80 mg/Day: Long‐Term Experience in a Large Group of Patients with Hypercholesterolemia. Clinical Cardiology. 23(1). 39–46. 28 indexed citations
17.
Stein, Evan A., Michael H. Davidson, Adrian S. Dobs, et al.. (1998). Efficacy and safety of Simvastatin 80 mg/day in hypercholesterolemic patients. The American Journal of Cardiology. 82(3). 311–316. 56 indexed citations
18.
Davidson, Michael, Stuart Weiss, R. Knopp, et al.. (1997). The Efficacy and Six-Week Tolerability of Simvastatin 80 and 160 mg/Day. The American Journal of Cardiology. 79(1). 38–42. 146 indexed citations
19.
Raal, Frederick J., Gillian J. Pilcher, D. Roger Illingworth, et al.. (1997). Expanded-dose simvastatin is effective in homozygous familial hypercholesterolaemia. Atherosclerosis. 135(2). 249–256. 81 indexed citations
20.
McPherson, Ruth, Malcolm G. Baines, A. Vost, et al.. (1993). Effects of lovastatin on natural killer cell function and other immunological parameters in man. Journal of Clinical Immunology. 13(6). 439–444. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Deepak Voora Breakdown of academic impact, for papers by Junji Koizumi Breakdown of academic impact, for papers by A.F.H. Stalenhoef Breakdown of academic impact, for papers by Pedro Mata Breakdown of academic impact, for papers by James H. Revkin Breakdown of academic impact, for papers by Marina Cuchel Breakdown of academic impact, for papers by Núria Plana Breakdown of academic impact, for papers by Claude Gagné Breakdown of academic impact, for papers by M. John Chapman Breakdown of academic impact, for papers by Rex A. Parker
Rankless by CCL
2026